Evidence map›Paper›PMID 42373911›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026

Breaking barriers: Implementation of a tuberculosis preventive treatment protocol among newly eligible populations with promising results.

Paloma Gijón, Teresa Aldámiz, Ana Isabel Ramos-Lisbona, Flor Valenzuela, Cristina Rincón, Raquel Carrillo, Patricia Muñoz, Maria Jesus Ruiz-Serrano

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Paloma GijónServicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Servicio de Microbiología Clínica. C/Dr. Esquerdo 47, Madrid, 28007, Spain. palomagijon@netscape.net.ORCID https://orcid.org/0000-0002-5011-1927
Teresa AldámizServicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Servicio de Microbiología Clínica. C/Dr. Esquerdo 47, Madrid, 28007, Spain.ORCID http://orcid.org/0000-0002-4374-6940
Ana Isabel Ramos-LisbonaServicio de Inmunología. Hospital Clínico San Carlos, Madrid, Spain.ORCID http://orcid.org/0009-0007-2727-1707
Flor ValenzuelaServicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Servicio de Microbiología Clínica. C/Dr. Esquerdo 47, Madrid, 28007, Spain.ORCID http://orcid.org/0009-0008-8942-7495
Cristina RincónServicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Servicio de Microbiología Clínica. C/Dr. Esquerdo 47, Madrid, 28007, Spain.ORCID http://orcid.org/0000-0001-8515-7434
Raquel CarrilloServicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Servicio de Microbiología Clínica. C/Dr. Esquerdo 47, Madrid, 28007, Spain.ORCID http://orcid.org/0000-0002-6389-0018
Patricia MuñozServicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Servicio de Microbiología Clínica. C/Dr. Esquerdo 47, Madrid, 28007, Spain.ORCID http://orcid.org/0000-0001-5706-5583
Maria Jesus Ruiz-SerranoServicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Servicio de Microbiología Clínica. C/Dr. Esquerdo 47, Madrid, 28007, Spain.ORCID http://orcid.org/0000-0002-2600-2771

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe World Health Organization emphasizes tuberculosis preventive treatment (TPT) as key to TB elimination. Implementation faces risk-benefit and adherence challenges. We implemented a structured TPT protocol at Hospital Gregorio Marañón with telephone support, personalized selection of currently available regimens, and toxicity management.

objectiveTo assess the structured TPT protocol in achieving complete preventive treatment (CPT) and identify factors associated with non-completion (NCPT).

methodsRetrospective analysis of a prospective cohort (2017-2024) of adults referred to the TB Unit. All causes of TPT were included per Spanish guidelines, except people living with HIV, who are followed in a separate clinic. Demographics, comorbidities, and outcomes were prospective collected. Univariate and multivariable logistic regression were used to identify predictors.

resultsOf 554 patients, 542 (97.8%) initiated TPT: close TB contacts (37.6%), immunosuppression (27.9%), and indications for immunomodulatory therapy (34.5%). Overall CPT was 86.5% (80.3% in those > 75 years; 90.7% in ages 35-54). Cancer predicted NCPT (aOR 2.25; 95% CI 1.21-4.21; p = 0.011). Among 73 NCPT cases, toxicity was the main cause (42.5%), followed by voluntary withdrawal (27.4%), social problems (20.5%, mainly in young immigrants), intercurrent disease (9.6%, notably cancer). Polypharmacy (aOR 2.51; 95% CI 1.13-5.60; p = 0.023) and inflammatory disease (aOR 2.25; 95% CI 1.06-4.75; p = 0.034) independently predicted toxicity-related NCPT.

conclusionsThe structured TPT protocol was associated with high CPT rates (86.5%), with excellent safety. Cancer predicted NCPT, polypharmacy and inflammatory disease predicted toxicity leading to NCPT. Similar studies are needed to compare our results.

Indexed as

ComorbidityLatent Tuberculosis InfectionsPreventive TreatmentStructured Protocol

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.